$1.5 million in R & D! FDA approved the release of bupropion hydrochloride sustained release tablets

On September 8, PLO pharmaceutical announced that its wholly-owned subsidiary Zhejiang Jutai Pharmaceutical Co., Ltd had recently received a notice from the U.S Food and Drug Administration (hereinafter referred to as the "U.S FDA"), and the brief application for new drugs of bupropion hydrochloride sustained release tablets (anda, the U.S generic application) declared by its company to the U.S FDA had been approved Bupropion hydrochloride sustained release tablets are suitable for the treatment of moderate and severe depression and seasonal affective disorder The drug was developed by Valeant international Barbados Sr and launched in the United States on August 28, 2003 At present, the main manufacturers of bupropion hydrochloride sustained-release tablets in the United States are par, Teva, etc.; at present, there is no product of this dosage form on the market in China According to the relevant market sales data, the sales volume of 300mg dosage form of the product in the U.S generic drug market in 2018 is about 120 million US dollars The product is jointly developed by PLO pharmaceutical and tulex Pharmaceutical Co Ltd of the United States Up to now, PLO pharmaceutical has invested about 1.5 million US dollars in the research and development of bupropion hydrochloride sustained-release tablets The announcement shows that bupropion hydrochloride sustained-release tablet is the first generic drug approved by the FDA of the United States by PLO pharmaceutical industry The number of approval of the FDA of the United States indicates that PLO pharmaceutical industry has the qualification to sell in the U.S market, has a positive role in promoting its company to expand the overseas market of generic drugs, is also in line with the strategic goal of coordinated development of its pharmaceutical business at home and abroad, and is public The company's future business performance has a certain positive impact Pulo pharmaceutical will also actively promote the preparation for the listing of the product in the future.